Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
Guttman-Yassky E, Vugmeyster Y, Lowes MA, Chamian F, Kikuchi T, Kagen M, Gilleaudeau P, Lee E, Hunte B, Howell K, Dummer W, Bodary SC, Krueger JG.
Guttman-Yassky E, et al. Among authors: gilleaudeau p.
J Invest Dermatol. 2008 May;128(5):1182-91. doi: 10.1038/jid.2008.4. Epub 2008 Jan 31.
J Invest Dermatol. 2008.
PMID: 18239614
Free article.
Clinical Trial.